Skip to main content

SUMO2/3 Antibody (SM23/496) - IHC-Prediluted

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-45335

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-45335
Conjugate
Catalog #

Key Product Details

Species Reactivity

Validated:

Human

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # SM23/496

Format

IHC-Prediluted

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Summary for SUMO2/3 Antibody (SM23/496) - IHC-Prediluted

Immunogen

Recombinant human SUMO2/3 protein

Reactivity Notes

Predicted to show a broad species reactivity.

Localization

Nuclear (SUMO-2); Cytoplasmic (SUMO-3)

Specificity

This monoclonal antibody reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimers disease.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Description

The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining.

Scientific Data Images for SUMO2/3 Antibody (SM23/496) - IHC-Prediluted

Immunohistochemistry-Paraffin: SUMO2/3 Antibody (SM23/496) - IHC-Prediluted [NBP2-45335]

Immunohistochemistry-Paraffin: SUMO2/3 Antibody (SM23/496) - IHC-Prediluted [NBP2-45335]

Immunohistochemistry-Paraffin: SUMO2/3 Antibody (SM23/496) - IHC-Prediluted [NBP2-45335] - Formalin-fixed, paraffin-embedded human tonsil stained with SUMO-2 MAb (SM23/496)

Applications for SUMO2/3 Antibody (SM23/496) - IHC-Prediluted

Application
Recommended Usage

Immunohistochemistry-Paraffin

0.5 - 1.0 ug/ml
Application Notes
Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
Optimal dilution for a specific application should be determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

10 mM PBS with 0.05% BSA

Format

IHC-Prediluted

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: SUMO2/3

Small Ubiquitin-like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed SUMOylation. There are four known SUMOs (SUMO1-4). All SUMO proteins share a conserved Ubiquitin domain and a C-terminal diglycine cleavage/attachment site. Following cleavage of a C-terminal prosegment, the C-terminal glycine residue of SUMO is enzymatically attached to a lysine residue on a target protein. In humans, SUMO is conjugated to a variety of molecules in the presence of the SAE1/UBA2 SUMO-activating (E1) enzyme and the UBE2I/Ubc9 SUMO-conjugating (E2) enzyme. In yeast, the SUMO-activating (E1) enzyme is Aos1/Uba2p. SUMOylation can occur without the requirement of a specific SUMO ligase (E3), where SUMO is transferred directly from UBE2I/Ubc9 to specific substrates. Unlike SUMO1, which is usually conjugated to proteins as a monomer, SUMO2 and SUMO3 are known to form high molecular weight polymers on proteins. SUMO precursor processing and deconjugation are catalyzed by a family of cysteine proteases known as SUMO-specific proteases (SENPs) and DeSUMOylating Isopeptidase 1.

Long Name

Small Ubiquitin-like Modifier 2, & 3

Alternate Names

HSMT3, small ubiquitin-like modifier 2, SMT3A, SMT3B, SMT3H2, SUMO2, SUMO3

Gene Symbol

SUMO2

Additional SUMO2/3 Products

Product Documents for SUMO2/3 Antibody (SM23/496) - IHC-Prediluted

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SUMO2/3 Antibody (SM23/496) - IHC-Prediluted

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...